FDA Clears Surrozen's SZN-8141 IND, Triggering $95.1M Financing
SRZN has more than doubled off its 52-week low of $11.39.
Summary
Surrozen's IND for SZN-8141, a dual-mechanism Wnt agonist/VEGF antagonist for diabetic macular edema, is now effective, allowing the company to start the DUET Phase 1b/2a trial with first patient dosing expected in Q4 2026. This clearance also satisfies the milestone for the second closing of the March 2025 private placement, expected to bring in approximately $95.1 million in gross proceeds around October 20, 2026. The financing is critical given the company's going concern warning and $127.5 million Q1 net loss. Initial data from DUET is expected in the second half of 2027.
At the time of this announcement, SRZN was trading at $30.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $352.6M. The 52-week trading range was $11.39 to $37.83. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.